Atherosclerosis
Volume 205, Issue 2 , Pages 357-359 , August 2009

ADMA and SDMA levels in healthy men exposed to tobacco smoke

  • Andrzej Sobczak

      Affiliations

    • Department of General and Analytical Chemistry, Medical University of Silesia, 4 Jagiellonska St., 41-200 Sosnowiec, Poland
    • Department of Chemical Hazards, Institute of Occupational Medicine and Environmental Health, 13 Koscielna St., 41-200 Sosnowiec, Poland
    • Corresponding Author InformationCorresponding author at: Department of General and Analytical Chemistry, Medical University of Silesia, 4 Jagiellonska St., 41-200 Sosnowiec, Poland. Tel.: +48 32 3641564; fax: +48 32 3641134.
    • ,
  • Maciej Lukasz Goniewicz

      Affiliations

    • Department of General and Analytical Chemistry, Medical University of Silesia, 4 Jagiellonska St., 41-200 Sosnowiec, Poland
    • Center for Tobacco Control Research and Education, University of California San Francisco, 530 Parnasus Ave., Suite 366, San Francisco, CA 94143-1390, USA
    • ,
  • Izabela Szoltysek-Boldys

      Affiliations

    • Department of General and Analytical Chemistry, Medical University of Silesia, 4 Jagiellonska St., 41-200 Sosnowiec, Poland

Received 4 August 2008

References 

  1. D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation. 2008;117:743–753
  2. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med. 2003;138:891–897
  3. Dayal S, Lentz SR. ADMA and hiperhomocysteinemia. Vasc Med. 2005;10:S27–S33
  4. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572–575
  5. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J. 2006;152:493e1–8
  6. Bode-Böger SM, Scalera F, Kielstein JT, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol. 2006;17:1128–1134
  7. Teerlink T. Determination of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in biological samples by HPLC. Methods Mol Med. 2004;108:263–274
  8. Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between obesity, smoking and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism. 2004;53:1574–1579
  9. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res. 2005;97:e53–e59
  10. Zhang WZ, Venardos K, Chin-Dusting J, Kaye DM. Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress. Hypertension. 2006;48:278–285
  11. Wang J, Sim AS, Wang XL, et al. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis. 2006;184:383–388
  12. Maas R, Schulze F, Baumert J, et al. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem. 2007;53:693–701
  13. Meinitzer A, Seelhorst U, Wellnitz B, et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem. 2007;53:273–283
  14. Kielstein JT, Peter C, Adams MC. Cigarettes and ADMA: the smoke hasn’t cleared yet. Hypertension. 2006;48:E20
  15. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 2003;24:1912–1919
  16. Schiel R, Franke S, Busch M, et al. Effect of smoking on risk factors for cardiovascular disease in patients with diabetes mellitus and renal insufficiency. Eur J Med Res. 2003;8:283–291
  17. Lenzen H, Tsikas D, Böger RH. Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter CARDIAC study. Eur J Clin Pharmacol. 2006;62:45–49
  18. Tonstad S, Thorsrud H, Torjesen PA, Seljeflot I. Do novel risk factors differ between men and women aged 18 to 39 years with a high risk of coronary heart disease?. Metabolism. 2007;56:260–266

PII: S0021-9150(09)00007-0

doi: 10.1016/j.atherosclerosis.2008.12.039

Atherosclerosis
Volume 205, Issue 2 , Pages 357-359 , August 2009

Article Tools